ExodusPoint Capital Management LP Purchases Shares of 69,277 GoodRx Holdings, Inc. (NASDAQ:GDRX)

ExodusPoint Capital Management LP purchased a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 69,277 shares of the company's stock, valued at approximately $322,000.

Other institutional investors have also recently modified their holdings of the company. Barclays PLC boosted its stake in shares of GoodRx by 1,316.1% during the 3rd quarter. Barclays PLC now owns 140,113 shares of the company's stock worth $973,000 after acquiring an additional 130,219 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in GoodRx by 5.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company's stock worth $3,332,000 after purchasing an additional 26,262 shares in the last quarter. IMC Chicago LLC acquired a new stake in GoodRx in the fourth quarter valued at $304,000. Franklin Resources Inc. purchased a new position in shares of GoodRx in the third quarter valued at $5,675,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of GoodRx during the 4th quarter worth $358,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Price Performance

Shares of GDRX stock remained flat at $4.49 during trading hours on Tuesday. 747,078 shares of the stock traded hands, compared to its average volume of 1,379,576. The business's 50-day moving average price is $4.64 and its two-hundred day moving average price is $5.03. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. GoodRx Holdings, Inc. has a 1-year low of $3.82 and a 1-year high of $9.26. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -149.67, a PEG ratio of 2.46 and a beta of 1.25.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on GDRX shares. Wells Fargo & Company lowered their price objective on shares of GoodRx from $9.00 to $8.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Truist Financial dropped their price objective on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a research note on Thursday, April 10th. Morgan Stanley reduced their target price on GoodRx from $7.00 to $6.00 and set an "equal weight" rating on the stock in a research note on Tuesday, December 17th. KeyCorp cut their price target on GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Finally, Citigroup decreased their price objective on GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a research note on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $7.93.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.